Recent advances in adenosine receptor antagonist research

Bibliography

• RALEVIC V, BURNSTOCK G: Receptors for purines and pyrimidines. Pharmacol Rev (1998) 50(3):413–492.
   PubMed Web of Science ®Google Scholar
• ••In depth review on current knowledge ofpurine and pyrimidine receptors.
   Google Scholar
• JACOBSON KA: Probing adenosine and P2 receptors: design of novel purines and nonpurines as selective ligands. Drug Develop. Res. (2001) 52(1-2):178–186.
   Google Scholar
• •Review on ligands developed in the Molecular Recognition Section, LBC, NIDDK, NIH.
   Google Scholar
• POULSEN SA, QUINN RJ: Adenosine: new opportunities for future drugs. Bioorg. Med. Chem. (1998) 6:619–641.
   PubMed Web of Science ®Google Scholar
• •Therapeutic potential of AR antagonists.
   Google Scholar
• MOLLER CE: Al-Adenosine receptor. Expert Opin. Ther. Pat. (1997) 7(5):419–440.
   Google Scholar
• •Therapeutic potential of A1 AR antagonists.
   Google Scholar
• BARALDI PG, CACCIARI B, R et al.: A3 adenosine receptor ligands: history and perspectives. Med. Res. Rev (2000) 20(2):103–128.
   PubMed Web of Science ®Google Scholar
• •Synthesis and SARs of A3 ligands.
   Google Scholar
• KOUROUNAKIS AP VAN DER KLEIN PAM, IJZERMAN AP: Elucidation of structure-activity relationships of 2-amino-3-benzoylthiophenes: study of their allosteric enhancing v. antagonistic activity on adenosine A1 receptors. Drug Develop. Res. (2000) 49(4):227–237.
   Google Scholar
• SORBERA LA, MARTIN L, CASTANER J: CPX, Drugs Future (2000) 25(10):1011–1016.
   Google Scholar
• BRUNS RF, FERGUS JH: Solubilities of adenosine antagonists determined by radioreceptor assay. j Pharm. Pharmacol (1989) 41(9):590–594.
   PubMedGoogle Scholar
• MOLLER CE, STEIN B: Adenosine receptor antagonists: structures and potential therapeutic applications. Curr. Pharm. Des. (1996) 2(5):501–530.
   Google Scholar
• ••In depth review on AR antagonists andtheir therapeutic applications.
   Google Scholar
• KLOTZ KN, HESSLING J, HEGLER J et al.: Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells. Naurtyri-'s Arch. Pharmacol (1998) 357(1):1–9.
   PubMedGoogle Scholar
• ••First comparison of adenosine ligands athuman receptor subtypes.
   Google Scholar
• KLOTZ KN: Adenosine receptors and their ligands. Naurtyri-Schmiedeberg's Arch. Pharmacol (2000) 362(4-5):382–391.
   PubMedGoogle Scholar
• ••Review on adenosine ligands at humanreceptors.
   Google Scholar
• MOLLER CE: Adenosine receptor ligands - recent developments. Part 1. Agonists. Curr. Med. Chem. (2000) 7(12):1269–1288.
   Google Scholar
• ••Recent overview on adenosine agonists.
   Google Scholar
• KULL B, ARSLAN G, NILSSON C etal.: Differences in the order of potency for agonists but not antagonists at human and rat adenosine A2A receptors. Biochem. Pharmacol (1999) 57(1):65–75.
   Google Scholar
• •Species differences.
   Google Scholar
• DALPIAZ A, TOWNSEND-NICHOLSON A, BEUKERS MW SCHOFIELD PR, IJZERMAN AP: Thermodynamics of full agonist, partial agonist, and antagonist binding to wild-type and mutant adenosine A1 receptors. Biochem. Pharmacol. (1998) 56(11):1437–1445.
   PubMedGoogle Scholar
• SHRYOCK JC, OZECK MJ, L: Inverse agonists and neutral antagonists of recombinant human A1 adenosine receptors stably transfected in Chinese Hamster Ovary cells. Ma Pharmacol (1998) 53(5):886–893.
   PubMedGoogle Scholar
• •Characterisation of inverse agonists versus antagonists.
   Google Scholar
• PINTOR J, MIRAS-PORTUGAL MT, FREDHOLM BB: Research on purines and their receptors comes of age. Trends Pharmacol Sci. (2000) 21 (12):453–456.
   PubMedGoogle Scholar
• WILLIAMS M, JARVIS MF: Purinergic and pyrimidinergic receptors as potential drug targets. Biochem. Pharmacol (2000) 59(10):1173–1185.
   PubMedGoogle Scholar
• BARALDI PG, CACCIARI B, ROMAGNOLI R et al: A1 and A3 adenosine receptor agonists: an overview. Expert. Opin. Ther. Pat. (1999) 9(5):515–527.
   Web of Science ®Google Scholar
• OLAH ME, STILES GL: The role of receptor structure in determining adenosine receptor activity. Pharmacol Ther. (2000) 85(2):55–75.
   PubMedGoogle Scholar
• NYCE JW: Insight into adenosine receptor function using antisense and gene knockout approaches. Trends Pharmacol Sci. (1999) 20(2)79–83
   Google Scholar
• FEOKTISTOV I, BIAGGIONI I, POLOSA R, HOLGATE ST: Adenosine A2B receptors: a novel therapeutic target in asthma? Trends Pharmacol Li. (1998) 19(4):148–153
   Google Scholar
• VAN MUIJLWIJK-KOEZEN JE, TIMMERMAN H, IJZERMAN AP: The adenosine A3 receptor and its ligands. In: Prog. Med. Chem. King FD, Oxford AW (Eds.), Elsevier Science, Amsterdam (2001) 38:61–180.
   Google Scholar
• DALY JW: Adenosine receptors: targets for future drugs. J. Med. Chem. (1982) 25(3):197–207.
   PubMedGoogle Scholar
• JACOBSON KA, VAN GALEN PJ, WILLIAMS M: Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential. ..J. Med. Chem. (1992) 35(3):407–422.
   PubMedGoogle Scholar
• VAN DER LEYEN H, SCHMITZ W, SCHOLZ H, SCHOLZ J, LOHSE MJ, SCHWABE U: Effects of 1,3-dipropy1-8-cyclopentylxanthine (DPCPX), a highly selective adenosine receptor antagonist, on force of contraction in guinea-pig atrial and ventricular cardiac prepartions. Naurtyri Schmiedeberg's Arch. Pharmacol. (1989) 340 (2): 204–209.
   PubMedGoogle Scholar
• ARISPE N, MA J, JACOBSON KA, POLLARD HB: Direct activation of cystic fibrosis transmembrane conductance regulator channels by 8-cyclopenty1-1,3-dipropylxanthine (CPX) and 1,3-dially1-8-cyclohexylxanthine (DAX). I Biol. Chem. (1998) 273(10):5727–5734.
   Google Scholar
• •Effects of DPCPX on cystic fibrosis.
   Google Scholar
• JACOBSON KA, BARONE S, U, STILES GL: Electrophilic derivatives of purines as irreversible inhibitors of A1 Adenosine receptors. j Med. Chem. (1989) 32(5):1043–1051.
   PubMedGoogle Scholar
• BEAUGLEHOLE AR, BAKER SP, SCAMMELLS PJ: Fluorosulfonyl-substituted xanthines as selective irreversible antagonists for the Al-adenosine receptor. Med. Chem. (2000) 43(26):4973–4980.
   Google Scholar
• VAN MUIJLWIJK-KOEZEN JE, TIMMERMAN H, VAN DER SLUIS RP et al.: Synthesis and use of FSCPX, an irreversible adenosine Al antagonist, as a 'receptor knock-down' tool. Bioorg. Med. Chem. (2001) 11(6):815–818.
   Google Scholar
• CECCARELLI S, D'ALESSANDRO A, PRINZIVALLI M, ZANARELLA S: Imidazo11,2-alquinoxalin-4-amines: a novel class of non-xanthine Al-adenosine receptor Eur. I Med. Chem. (1998) 33(12):943–955.
   Google Scholar
• •AR antagonists with in vivo activity.
   Google Scholar
• PORSOLT RD, BERTIN A, JALFRE M: Behavioural despair in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther. (1977) 229(2):327–336.
   PubMedGoogle Scholar
• STERU L, CHERMAT R, THIERRY B, SIMON P: The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (1985) 85(3):367–370.
   PubMed Web of Science ®Google Scholar
• KURODA S, AKAHANE A, ITANI H et al.: Discovery of FR166124, a novel water-soluble pyrazolo [1, 5-alpyridine adenosine A1 receptor antagonist. Bioorg. Med. Chem. Lett. (1999) 9(14):1979–1984.
   PubMedGoogle Scholar
• AKAHANE A, KATAYAMA H, T et al.: Discovery of 6-oxo-3-(2-phenylpyrazolo[1,5-alpyridin 3 yl) 1(61-4-pyridazinebutanoic acid (FK838): a novel non-xanthine adenosine A1 receptor antagonist with potent diuretic activity. Med. Chem. (1999) 42(5):779–783.
   Google Scholar
• ••A1 antagonists as potent diuretics.
   Google Scholar
• KURODA S, AKAHANE A, ITANI H et al.: Novel adenosine A1 receptor antagonists. Synthesis and structure-activity relationships of a novel series of 3- (2-cyclohexeny1-3-oxo-2,3-dihydropyridazin-6-y1)-2-phenylpyrazolo[1,5-a]pyridines. Bioorg. Med. Chem. (2000) 8(1):55–64.
   Google Scholar
• MOLLER CE, GETS U, GRAHNER B, LANZNER W, EGER K: Chiral [2,3-d]pyrimidine and pyrimido[4,5-b]indole derivatives: structure-activity relationships of potent, highly stereoselective Al-adenosine receptor antagonists. I Med. Chem. (1996) 39(13):2482–2491.
   PubMedGoogle Scholar
• HESS S, MOLLER CE, FROBENIUS W, REITH U, KLOTZ KN, EGER K: 7-Deazaadenines bearing polar substituents: structure-activity relationships of new A1 and A3 adenosine receptor antagonists. Med. Chem. (2000) 43(24):4636–4646.
   Google Scholar
• •Fluorescent deazaadenines with high affinity at human AR.
   Google Scholar
• MOLLER CE: A1 adenosine receptors and their ligands: overview and recent developments. Farmaco (2001) 56(1-2):77–80.
   PubMedGoogle Scholar
• ESCHKE D, BRAND A, SCHEIBLERP etal.: Effects of an adenosine A1 receptor agonist and a novel pyrimidoindole on membrane properties and neurotransmitter release in rat cortical and hippocampal. Neurochem. mt. (2001) 38(5):391–398.
   Google Scholar
• CAMPBELL RIVI, CARTWRIGHT C, CHEN W et al.: Selective Al-adenosine receptor antagonists identified using yeast Saccharomyces cerevisiae functional assays. Bioorg. Med. Chem. Lett. (1999) 9(16):2413–2418.
   PubMedGoogle Scholar
• POULSON SA, YOUNG DJ, QUINN RJ: High-pressure synthesis of enantiomerically pure C-6 substituted pyrazolo [3,4-d]pyrimidines. Bioorg. Med. Chem. Lett. (2001) 11(2):191–193.
   PubMedGoogle Scholar
• CHEBIB M, McKEVENEY D, QUINN RJ: 1-Phenylpyrazolo [3,4- dlpyrimidines; Structure-activity relationships for C6 substitutents at A1 and kik adenosine receptors. Bioorg. Med. Chem. (2000) 8(10:2581–2590.
   PubMedGoogle Scholar
• FERRARINI PL, MORI C, MANERA C etal.: A novel class of highly potent and selective A1 adenosine antagonists: structure-affinity profile of a series of 1,8-naphthyridine derivatives. I Med Chem. (2000) 43(15):2814–2823.
   Google Scholar
• DA SETTIMO F, PRIMOFIORE G, TALIANI S et al.: 3-Ary1[1,2,41triazino [4,3-a]benzimidazol-4(1014-ones: a new class of selective A1 adenosine receptor antagonists.. Chem. (2001) 44(3):316–327.
   Google Scholar
• IJZERMAN AE VAN GALEN PJM, JACOBSON KA: Molecular modelling of adenosine receptors. I. The ligand binding site on the A1 receptor. Drug Des. Discov. (1992) 9(1):49–67
   Google Scholar
• COLOTTA V, CATARZI D, VARANO F etal.: 1,2,4-Triazolo [4,3-a] quinoxalin-1 - one: a versatile tool for the synthesis of potent and selective adenosine receptor antagonists. I Med. Chem. (2000) 43(6):1158–1164.
   Google Scholar
• COLOTTA V, CATARZI D, VARANO F et al.: Synthesis and structure-activity relationships of a new set of 2- [34-c]quinoline derivatives as receptor antagonists. I Med. Chem. (2000) 43(16):3118–3124.
   PubMedGoogle Scholar
• VAN MUIJLWIJK-KOEZEN JE, TIMMERMANN H, VOLLINGA RC et al.: Thiazole and thiadiazole analogues as a novel class of adenosine receptor antagonists. I Med. Chem. (2001) 44(5):749–762.
   PubMed Web of Science ®Google Scholar
• SCAMMELLS PJ, BAKER SE AR: XH-14 analogues as adenosine antagonists. Bioorg. Med. Chem. (1998) 6(9):1517–1524.
   PubMedGoogle Scholar
• BARALDI PG, ZAID AN, LAMPRONTI et al.: Synthesis and biological effects of a new series of 2-amino-3-benzoylthiophenes as allosteric enhancers of Al-adenosine receptor. Bioorg. Med. Chem. Lett. (2000) 10(17):1953–1957.
   PubMedGoogle Scholar
• KOUROUNAKIS A1 VISSER C, DE GROOTE M, IJZERMAN AP: Allosteric modulation of the rat adenosine A1 receptor: differential effects on agonist and antagonist binding. Drug Develop. Res. (2000) 51(4):207–215.
   Google Scholar
• LIBERT F, PARMENTIER M, LEFORT A et al.: Selective amplification and cloning of four new members of the G protein-coupled receptor family. Science (1989) 244(4904):569–572.
   PubMed Web of Science ®Google Scholar
• ONGINI E, FREDHOLM BB: Pharmacology of adenosine A2A receptors. Trends PharmacoL Sci. (1996) 17(10):364–372.
   PubMedGoogle Scholar
• LINDEN J: Cloned adenosine A3 receptors: pharmacological properties, species differences and receptor functions. Trends PharmacoL Li. (1994) 15(8):298–306.
   PubMed Web of Science ®Google Scholar
• LEDENT C, VAUGEOIS J-M, SCHIFFMANN SN et al.: Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2A receptor. Nature (1997) 388(6643):674–678.
   PubMedGoogle Scholar
• ••Study on A2A knockout mice.
   Google Scholar
• SVENNINSSON E LE MOINE C, FISONE G, FREDHOLM BB: Distribution, biochemistry and function of striatal adenosine A2A receptors. Prog. NeurobioL (1999) 59(4):355–396.
   PubMedGoogle Scholar
• FERRE S, POPOLI E GIMENES-LLORT et al.: Adenosine/dopamine interaction: implications for the treatment of Parkinson's disease. Parkinsonisrn and Relat. Disord. (2001) 7(3):235–241.
   Google Scholar
• MOLLER CE: A2A adenosine receptor antagonists - future drugs for Parkinson's disease? Drugs Future (2000) 25(10):1043–1052.
   Google Scholar
• EL YACOUBI M, LEDENT C, PARMENTIER M, COSTENTIN J, VAUGEOIS JM: The anxiogenic-like effects of caffeine in two experimental procedures measuring anxiety in the mouse is not shared by selective A2A adenosine receptor antagonists. Psychopharmacology (2000) 148(2):153–163.
   PubMedGoogle Scholar
• EL YACOUBI M, LEDENT C, PARMENTIER M, COSTENTIN J, VAUGEOIS JM: 5CH58261 and ZM241385 differently prevent the motor of CGS21680 in mice. Evidence for a functional 'atypical' adenosine A2A receptor. Eur. j Pharmacol. (2000) 401(1):63–77.
   Google Scholar
• KELLY JS: Alzheimer's disease: the terrine legacy. Trends Pharmacol Sci (1999) 20(4):127–129.
   PubMedGoogle Scholar
• WINBLAD B, WIMO A: Assessing the societal impact of acetylcholinesterase inhibitor therapies. Alzheimer Dis. Assoc. Disord. (1999) 13(S2):S9–19.
   PubMedGoogle Scholar
• RABASSEDA X, SORERA LA, MARTIN, LESSON PA, CASTANER J: KW-6002. Antiparkinsonian - Antidepressant - adenosine A2A antagonist. Drugs Future (2001) 26(1):20–24.
   Google Scholar
• AOYAMA S, KASE H, BORELLI E: Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist.. (2000) 20(15):5848–5852.
   Google Scholar
• MOLLER CE, SAND OVAL-RAMIREZJ, SCHOBERT U, GEIS U, FROBENIUS W, KLOTZ KN: 8- (Sulfostyry9 xanthines: water-soluble A2A-selective adenosine receptor antagonists. Bioorg. Med. Chem. (1998) 6(6):707–719.
   PubMedGoogle Scholar
• SAUER R, MAURINSH J, REITH U, HALE F, KLOTZ KN, MOLLER CE:-soluble phosphate prodrugs of 1 - propargy1-8-styrylxanthine derivatives, A-A-selective adenosine receptor antagonists. Med. Chem. (2000) 43(3):440–448.
   Google Scholar
• ••Development of potent prodrugs at AzAAR.
   Google Scholar
• HAUBER W, NAGEL J, SAUER R, MOLLER CE: Motor effects induced by a blockade of adenosine A2A receptors in the caudate-putamen. Neuroreport (1998) 9(8):1803–1806.
   PubMedGoogle Scholar
• STROMBERG I, POPOLI P, MOLLER CE, FERRE S, FUXE K: and behavioural evidence for an antagonistic modulatory role of adenosine A2A receptors in dopamine D2 receptor regulation in the rat dopamine-denervated striatum. Eur. j Neurosci. (2000) 12(11):4033–4037.
   PubMed Web of Science ®Google Scholar
• •In vivo activity of AzA antagonists.
   Google Scholar
• MOLLER CE, MAURINSH J, SAUER R: of [31-11IVISX-2 (3- (3-hydroxypropy9-7-methy1-8-(m-methoxystyry9-1-propargylxanthine) to rat striatal membranes - a new, selective antagonist radioligand for A2A adenosine receptors. Eur. j Pharm. Sci. (2000) 10(4):259–265.
   PubMedGoogle Scholar
• CAMAIONI E, COSTANZI S, VITTORI S, VOLPINI R, KLOTZ KN, CRISTALLI G: New substituted 9-alkylpurines as adenosine receptor ligands. Bioorg. Med. Chem. (1998) 6(5):523–533.
   PubMedGoogle Scholar
• KIM YC, DE ZWART M, CHANG L et al.: Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes. j Med. Chem. (1998) 41(15):2835–2845.
   PubMedGoogle Scholar
• ••Development of highly potent A2B and A3antagonists.
   Google Scholar
• BARALDI PG, CACCIARI B, SPALLUTO G etal.: Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-Hpyrimidine derivatives: potent and selective A2A adenosine antagonists. I Med. Chem. (1996) 39(5):1164–1171.
   Google Scholar
• BARALDI PG, CACCIARI B, SPALLUTO G etal.: Design, synthesis, and biological evaluation of a second generation of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-Hpyrimidines as potent and selective A2A adenosine antagonists. I Med. Chem. (1998) 41(12):2126–2133.
   Google Scholar
• ••Development of highly potent A2Aantagonists.
   Google Scholar
• ONGINI E, DIONISOTTI S, GESSI S, IRENIUS E, FREDHOLM BB: Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors. Nautlyn-SchrniedebergS Arch. Pharmacol (1999) 359(1):7–10.
   PubMedGoogle Scholar
• TODDE S, MORESCO RM, SIMONELLI P et al: Design,, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A2A receptor system using positron emission tomography.. Chem. (2000) 43(23):4359–4362.
   Google Scholar
• •Study of 5CH442416, a very potent A2A antagonist.
   Google Scholar
• BARALDI PG, BOREA PA, M etal.: Comparative molecular field analysis (CoMFA) of a series of selective adenosine receptor A2A antagonists. Drug Develop. Res. (1999) 46(2):126–133.
   Google Scholar
• KIM J, WESS J, VAN RHEE AM, SCHONEBERG T, JACOBSON KA: Site- mutagenesis identifies residues involved in ligand recognition in the human A2A adenosine receptor. j Biol. Chem. (1995) 270(23):13987–13997.
   PubMedGoogle Scholar
• •A2A model based on bacteriorhodopsin.
   Google Scholar
• GAO ZG, JIANG Q, JACOBSON KA, UZERIVIAN AP: Site-directed mutagenesis studies of human A2A adenosine receptors. of G1u13 and His278 in ligand binding and sodium modulation. Biochem. Pharmacol (2000) 60(5):661–668.
   Google Scholar
• PALCZEWSKI K, KUMASAKA T, HORI T et al: Crystal structure of rhodopsin: a G protein-coupled receptor. Science (2000) 289(5480):739–745.
   PubMed Web of Science ®Google Scholar
• GAO AG, IJZERMAN AP: Allosteric modulation of A2A adenosine receptors by amiloride analogues and sodium ions.. Pharmacol. (2000) 60(5):669–676.
   Google Scholar
• JACOBSON KA, UZERIVIAN AP, LINDEN J: 1,3-Dialkylxanthine derivatives having high potency as antagonists at human A2B adenosine receptors. Drug Develop. Res. (1999) 47(1):45–53.
   Google Scholar
• FEOKTISTOV I, BIAGGIONI I: Role of adenosine in asthma. Drug Develop. Res. (1996) 39(3-4):333–336.
   PubMedGoogle Scholar
• AUCHAMPACH JA, JINX, WAN TC, CAUGHEY GH, LINDEN J: Canine mast cell adenosine receptors: cloning and expression of the A3 receptor and evidence that degranulation is mediated by the A2B receptor. Mal Pharmacol (1997) 52:846–860.
   PubMed Web of Science ®Google Scholar
• KIM YC, KARTON Y, JI XD, MELMAN N, LINDEN J, JACOBSON KA: Acyl-hydrazide derivatives of a xanthine carboxylic congener (XCC) as selective antagonists at human A2B adenosine receptors. Drug Develop. Res. (1999) 47(4):178–188.
   PubMedGoogle Scholar
• •XCC derivatives as A2B antagonists.
   Google Scholar
• KIM YC, JI XD, MELMAN N, LINDEN J, JACOBSON KA: Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A2B adenosine receptors. j Med. Chem. (2000) 43(6):1165–1172.
   PubMedGoogle Scholar
• JI XD, KIM YC, AHERN DG, LINDEN J, JACOBSON KA: [3H1MRS 1754, a selective antagonist radioligand for A2B adenosine receptors. Biochem. Pharmacol (2001) 61(6):657–663.
   PubMedGoogle Scholar
• HARADA H, ASANO 0, HOSHINO Yet al.: 2-Alkyny1-8-aryl-9-methyladenines as novel adenosine receptor antagonists: their synthesis and structure-activity relationships toward hepatic glucose production induced via agonism of the A2B receptor. I Med. Chem. (2001) 44(2):170–179.
   Google Scholar
• ••Development of AR antagonists asantidiabetics.
   Google Scholar
• DE ZWART M, VOLLINGA RC, BEUKERS MW et al: Potent antagonists for the human adenosine A2B receptor. of the triazolotriazine adenosine receptor antagonist ZM241385 with high affinity. Drug Develop. Res. (1999) 48(3):95–103.
   Google Scholar
• ZHOU QY, LI C, OLAH ME, RA, STILES GL, CIVELLI 0: Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. Proc. Natl. Acad. Li. USA (1992) 89(16):7432–7436.
   PubMedGoogle Scholar
• •Characterisation of A3 AR.
   Google Scholar
• SALVATORE CA, JACOBSON MA, TAYLOR HE, LINDEN J, JOHNSON RG: Molecular cloning and characterization of the human A3 adenosine receptor. Proc. Natl. Acad. Li. USA (1993) 90(21):10365–10369
   PubMed Web of Science ®Google Scholar
• SAJJADI FG, BOYLE DL, DOMINGO RC, FIRESTEIN G: cDNA cloning and characterization of A3i, an alternatively spliced rat A3 adenosine receptor variant. FEBS Lett. (1996) 382(12):125–129.
   PubMedGoogle Scholar
• JINX, SHEPARD RK, DULLING BR, LINDEN J: Inosine binds to A3 adenosine receptors and stimulates mast cell degranulation. j Clin. Invest. (1997) 100(11):2849–2857.
   PubMedGoogle Scholar
• ZHAO Z, MAKARITSIS K, FRANCIS CE, GAVRAS H, RAVID K: A role for the A3 adenosine receptor in determining tissue levels of cAMP and blood pressure: studies in knock-out mice. Biochim. Biophys. Acta. (2000) 1500(3):280–290.
   PubMedGoogle Scholar
• WALKER BA, JACOBSON MA, KNIGHT DA etal.: Adenosine A3 receptor expression and function in eosinophils. Am. Resp. Cell MoL Biol. (1997) 16(5):531–537.
   Google Scholar
• JACOBSON KA, NIKODIJEVIC 0, SHI et al.: A role for central A3-adenosine receptors. Mediation of behavioural depressant effects. FEBS Lett. (1993) 336(1):57–60.
   Google Scholar
• BRAMBILLAR, CATTABENI F, CERUTI S etal.: Activation of the A3 adenosine receptor affects cell cycle progression and cell growth. Nailing] Schmiedeberg's Arch. Pharmacol. (2000) 361(3):225–234.
   Google Scholar
• YAO Y, SEI Y, ABBRACCHIO MP, JIANGJL, KIM YC, JACOBSON KA: Adenosine A3 receptor agonists protect HL-60 and U-937 cells from apoptosis induced by A3 antagonists. Biochem. Biophys. Res. Commun. (1997) 232(2):317–322.
   PubMedGoogle Scholar
• VAN MUIJLWIJK-KOEZEN JE, TIMMERMAN H, VAN DER GOOT H et al.: Isoquinoline and quinazoline urea as antagonists for the human adenosine A3 receptor. j Med. Chem. (2000) 43(11):2227–2238.
   Google Scholar
• •Interesting SARs.
   Google Scholar
• PALMER TM, HARRIS CA, COOTE J, STILES GL: Induction of multiple effects on adenylyl cyclase regulation by chronic activation of the human A3 adenosine receptor. Mol. Pharmacol. (1997) 52(4):632–640.
   PubMedGoogle Scholar
• JACOBSON MA, CHAKRAVARTY PK, JOHNSON RG, NORTON R.:Novel selective non-xanthine A3 adenosine receptor antagonists. Drug Dev. Res. (1996) 37(3):131.
   Google Scholar
• JI XD, MELMAN N, JACOBSON KA: Interactions of flavonoids and other phytochemicals with adenosine receptors. Med. Chem. (1996) 39(3):781–788.
   Google Scholar
• •Natural products as AR antagonists.
   Google Scholar
• MORO S, VAN RHEE AM, SANDERS LH, JACOBSON KA: Flavonoid derivatives as adenosine receptor antagonists: a comparison of the hypothetical receptor binding site based on a comparative molecular field analysis model. j Med. Chem. (1998) 41(1):46–52.
   PubMedGoogle Scholar
• JIANG JL, VAN RHEE AM, MELMAN N, JI XD, JACOBSON KA: 6-Pheny1-1,4-dihydropyridine derivatives as potent and selective A3 adenosine receptor antagonists. ?Med. Chem. (1996) 39(23):4667–4675.
   Google Scholar
• LI AH, MORO S, MELMAN N, JI XD, JACOBSON KA: Structure-activity relationships and molecular modeling of 3,5-diacy1-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. ?Med. Chem. (1998) 41(17):3186–3201.
   Google Scholar
• JIANG J, LI AH, JANG SY etal.: Chiral resolution and stereospecificity of 6-phenyl-4-phenylethyny1-1, 4-dihydropyridines as selective A3 adenosine receptor antagonists. ?Med. Chem. (1999) 42(16):3055–3065.
   Google Scholar
• JIANG J, VAN RHEE MA, CHANG L et al.: Structure-activity relationships of 4-(phenylethyny1)-6-pheny1-1,4-dihydropyridines as highly selective A3 adenosine receptor antagonists. j Med. Chem. (1997) 40(16):2596–2608.
   PubMedGoogle Scholar
• XIE R, LI AH, JI XD et al.: Selective A3 adenosine receptor antagonists: water-soluble 3,5-diacy1-1,2,4-trialkylpyridinium salts and their oxidative generation from dihydropyridine precursors. I Med. Chem. (1999) 42(20):4232–4238.
   PubMedGoogle Scholar
• •Prodrug approach
   Google Scholar
• LI AH, MORO S, FORSYTH N, MELMAN N, JI XD, JACOBSON KA: Synthesis, CoMFA analysis and receptor docking of 3, 5-diacy1-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. j Med. Chem. (1999) 46(4):706–721.
   Google Scholar
• LI AH, JI XD, KIM HS, MELMAN N, JACOBSON KA: Pyran template approach to the design of novel A3 adenosine receptor antagonists. Drug Develop. Res. (1999) 48(4):171–177.
   PubMedGoogle Scholar
• PROKAI L, PROKAI-TATRAI K, BODOR N: Targeting drugs to the brain by redox chemical delivery systems. Med. Eec. Rev (2000) 20(5):367–416.
   Google Scholar
• KIM YC, JI XD, JACOBSON KA: Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) are selective for the human A3 receptor subtype.. Chem. (1996) 39(21):4142–4148.
   Google Scholar
• BARALDI PG, CACCIARI B, ROMAGNOLI R et al.: Pyrazolo l4, 3 - el 1, 2,4-triazolo [1,5-cl pyrimidine derivatives as highly potent and selective human A3 adenosine receptor antagonists: influence of the chain at the N8 pyrazole nitrogen. j Med. Chem. (2000) 43(25)4768–4780.
   Google Scholar
• ••Development of highly potent A3antagonists.
   Google Scholar
• BROWER V: Tumor angiogenesis - new drugs on the block. Nat. Biotech. (1999) 17(10):963–968.
   PubMedGoogle Scholar
• TAKAGI H, KING GL, ROBINSON GS, FERRARA N, AIELLO LP: Adenosine mediates hypoxic induction of vascular endothelial growth factor in retinal pericytes and endothelial cells. Invest. OphthalmoL Vis. Li. (1996) 37(11):2165–2176.
   PubMedGoogle Scholar
• KERBEL RS, VILORIA-PETIT A, KLEMENT G, RAK J: Accidental' anti-angiogenic drugs. Anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as example. Eur. j Cancer (2000) 36(10):1248–1257.
   Google Scholar
• BARALDI PG, CACCIARI B, ROMAGNOLI R et al.: Synthesis and preliminary biological evaluation of PH-MRE 3008-F20: the first high affinity radioligand antagonist for the human A3 adenosine receptors. Bioorg. Med. Chem. Lett. (2000) 10(3):209–211.
   PubMedGoogle Scholar
• •Development of highly potent A3 antagonists.
   Google Scholar
• VARANI K, MERIGHI S, GESSI S etal.: [31-11MRE 3008F20: a novel antagonist for the pharmacological and biochemical characterization of human A3 adenosine receptors. Mal Pharmacy] (2000) 57(5):968–9975.. MORO S, LI AH, JACOBSON KA: Molecular modeling of human A3 adenosine antagonists: structural homology and receptor docking. j Chem. Inf Comp. Sci. (1998) 38(6):1239–1248
   Google Scholar
• VAN MUIJLWIJK-KOEZEN JE, TIMMERMAN H, LINK R, VAN DER GOOT H, IJZERMAN AP: A novel class of adenosine A3 receptor ligands. 1. 3-(2-Pyridiny9isoquinoline derivatives. j Med. Chem. (1998) 41(21):3987–3993.
   Google Scholar
• VAN MUIJLWIJK-KOEZEN JE, TIMMERMAN H, LINK R, VAN DER GOOT H, IJZERMAN AP: A novel class of adenosine A3 receptor ligands. 2. Structure affinity profile of a series of isoquinoline and quinazoline compounds. Med. Chem. (1998) 41(21):3994–4000.
   Google Scholar
• WEBB TR, MELMAN N, LVOVSKIY D, JI XD, JACOBSON KA: The utilization of a unified pharmacophore query in the discovery of new antagonists of the adenosine receptor family. Bioorg. Med. Chem. Lett. (2000) 10(1):31–34.
   PubMedGoogle Scholar
• VAN DER KLEIN PAM, AP IJZERMAN AP: Allosteric modulation of the adenosine A1 receptor. Synthesis and biological evaluation of novel 2-amino-3-benzoylthiophenes as allosteric enhancers of agonist binding. Med. Chem. (1999) 42(18):3629–3635.
   Google Scholar
• FREDHOLM BB, FASTBOM J, KVANTA A, GERWINS E PARKINSON F: Further evidence that propentofylline (HWA 285) influences both adenosine receptors and adenosine transport. Fundam.. Pharmacy] (1992) 6 (3): 99–111.
   PubMedGoogle Scholar
• SHIMADA J, KOIKE N, NONAKA H et al.: Adenosine A2A antagonists with potent anti-cataleptic activity. Bioorg. Med. Chem. Lett. (1997) 7(18):2349–2352.
   Google Scholar